Page last updated: 2024-10-28

hexamethonium and Glomerulonephritis

hexamethonium has been researched along with Glomerulonephritis in 1 studies

Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

Glomerulonephritis: Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
RESTREPO, G1
BAUER, H1

Other Studies

1 other study available for hexamethonium and Glomerulonephritis

ArticleYear
Pneumonitis as a complication of hexamethonium therapy.
    Journal of chronic diseases, 1958, Volume: 7, Issue:3

    Topics: Glomerulonephritis; Hexamethonium; Hexamethonium Compounds; Humans; Hypertension; Pneumonia; Vascula

1958